Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications

AIMS: Direct‐acting antiviral agents (DAAs) for the treatment of hepatitis C (HCV) can be associated with drug–drug interactions (DDIs) with concomitant medications. The practical clinical implications of such DDIs are poorly understood. We assessed the clinical impact of possible pharmacokinetic (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Marra, Fiona, Höner zu Siederdissen, Christoph, Khoo, Saye, Back, David, Schlag, Michael, Ouwerkerk‐Mahadevan, Sivi, Bicer, Ceyhun, Lonjon‐Domanec, Isabelle, Jessner, Wolfgang, Beumont‐Mauviel, Maria, Kalmeijer, Ronald, Cornberg, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903235/
https://www.ncbi.nlm.nih.gov/pubmed/29345798
http://dx.doi.org/10.1111/bcp.13519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903235/
https://www.ncbi.nlm.nih.gov/pubmed/29345798
http://dx.doi.org/10.1111/bcp.13519

Ejemplares similares